US expedited review conditions change
This article was originally published in Clinica
The US FDA has issued guidance on the expedited review of premarket submissions for devices. Products are considered for expedited review if they are intended to treat or diagnose a life-threatening or debilitating condition or disease, or if they address an unmet medical need.
You may also be interested in...
Delay to Moderna's Phase III plans adds to the biotech's rollercoaster ride, but its CEO insists it is still on track.
This week's Device Week podcast covers recent regulatory developments in Asia in the wake of COVID-19, and how regulators are adjusting to working under the pandemic. Having published two updates from our regular Asian Medtech Associations Reg Networking discussions this week, Medtech Insight speaks to Asia Regulatory Professional Association founder Jack Wong on Asian regulatory themes and South Korea's hosting of the next International Medical Device School.
Currently serving at the WHO, Emer Cooke is set to return to the EMA later this year in the role of executive director. She will have to tackle challenges posed by Brexit, COVID-19 and recent agency restructuring.